Welcome to our dedicated page for Azenta SEC filings (Ticker: AZTA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. SEC filings for Azenta, Inc. (Nasdaq: AZTA), a life sciences company focused on cold-chain sample management and multiomics services. These regulatory documents offer detailed insight into how Azenta reports its financial performance, governance practices and executive compensation.
Core filings include the annual report on Form 10-K and quarterly updates on Form 10-Q, where Azenta discusses revenue from its Sample Management Solutions and Multiomics segments, separates products and services revenue, and explains trends in gross margin, operating expenses and adjusted EBITDA. Investors can review these filings to understand the contribution of sample storage, biorepository services and genomic analysis to the overall business.
Azenta’s current report filings on Form 8-K disclose material events such as quarterly and annual financial results, including segment performance and key metrics. For example, the company has furnished press releases detailing revenue growth, margin expansion and cash and liquidity positions, which are incorporated by reference into 8-K filings under Item 2.02.
The definitive proxy statement on Schedule 14A (DEF 14A) describes the structure of the Board of Directors, committee responsibilities, environmental, social and governance topics, and the executive compensation framework. It also outlines proposals submitted to shareholders, such as the election of directors, advisory votes on executive pay, amendments to the equity incentive plan and ratification of the independent auditor.
On Stock Titan, Azenta’s filings are updated as they appear on EDGAR, and AI-powered summaries can help explain lengthy documents like the 10-K, 10-Q, 8-K and DEF 14A. Users can quickly identify segment disclosures, non-GAAP reconciliations, compensation details and other key items without reading every page of the underlying filing.
Azenta, Inc. reports that the planned sale of B Medical Systems S.À R.L. to Thelema S.À R.L., entered into through a definitive Sale and Purchase Agreement by Azenta Germany GmbH, did not close by the previously expected date of on or before March 31, 2026 because Thelema has not yet secured the required financing. Thelema has indicated it needs additional time to complete its financing arrangements, and the transaction remains subject to all closing conditions, including this financing condition. The parties have not amended or terminated the agreement, and Azenta is evaluating potential paths forward while emphasizing that there can be no assurance the transaction will be completed on a revised timeline or at all.
Azenta Inc: The Vanguard Group filed an amendment on its Schedule 13G/A reporting 0 shares beneficially owned of Azenta Inc common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026 that disaggregated certain Vanguard subsidiaries' holdings per SEC Release No. 34-39538; following that realignment, those subsidiaries will report separately and Vanguard states it no longer is deemed to beneficially own securities held by those entities.
Azenta, Inc. announced that its wholly owned subsidiary Azenta UK Ltd has acquired all shares of UK Biocentre Limited, a UK-based provider of sample management, storage and high-throughput processing services. The total consideration is GBP 20.5 million, net of cash and including up to GBP 1.8 million of milestone-based contingent payments.
UK Biocentre is expected to operate as Azenta’s European-wide hub for Sample Repository Services and will retain its name. The business generated approximately GBP 15.3 million in revenue over the twelve months ending fiscal September 30, 2025. Azenta expects the deal to be dilutive to its 2026 Adjusted EBITDA margin by about 35 basis points, but accretive to organic revenue growth and Adjusted EBITDA margin expansion targets for 2027 and 2028.
Azenta, Inc. director William L. Cornog filed an amended insider report to fix an administrative error in his equity holdings. The correction relates to a grant of 5,663 restricted stock units with a zero exercise price. After the correction, he is reported to beneficially own 9,703 derivative securities tied to Azenta common stock directly.
Azenta, Inc. director Tina S. Nova received an equity grant of 5,663 common shares under the company’s 2020 Equity Incentive Plan. The grant consisted of unrestricted shares, and no amount was paid upon grant. Following this award, she beneficially owns 15,772 Azenta common shares directly.
Azenta, Inc. reported an equity award to director William L. Cornog. On 02/05/2026, he received 5,663 restricted stock units (RSUs), each representing one share of Azenta common stock. The RSUs were granted at $0.00 under the company’s 2020 Equity Incentive Plan, with no cash paid at grant.
The units are fully vested upon grant, but settlement of the shares is deferred. Cornog elected to receive the underlying common stock at the later of his reaching age 65 or his separation from service with the company. After this grant, he beneficially owns 5,663 derivative securities directly.
Azenta director Martin Madaus received 5,663 restricted stock units on February 5, 2026 under the company’s 2020 Equity Incentive Plan. Each unit represents one share of Azenta common stock and was granted at no cost to him.
The units are fully vested on grant, but Madaus elected to defer settlement until the later of reaching age 65 or leaving the company. Following this award, he beneficially owns 9,703 derivative securities in the form of restricted stock units held directly.
Azenta director Dipal Doshi reported a stock grant from the company. On February 5, 2026, Doshi received 5,663 shares of Azenta common stock as a grant of unrestricted shares under the Company’s 2020 Equity Incentive Plan at a reported price of $27.85 per share. No cash was paid for this award, and Doshi now directly owns 9,703 common shares following the transaction.
Azenta, Inc. director Frank Casal reported receiving a grant of 7,243 shares of Azenta common stock on February 5, 2026 under the company’s 2020 Equity Incentive Plan. According to the filing, no cash was paid for this unrestricted share award.
After this grant, Casal beneficially owns 21,803 Azenta common shares, held directly. The transaction is reported as an acquisition of non-derivative securities and reflects routine equity-based compensation for a board member.
Azenta, Inc. director Erica McLaughlin received a grant of 5,663 shares of Azenta common stock on February 5, 2026. The shares are unrestricted and were granted under the company’s 2020 Equity Incentive Plan, with no cash paid for the grant. Following this award, she directly holds 22,521 Azenta common shares.